George Tidmarsh
Chairman chez REVELATION BIOSCIENCES, INC.
Fortune : 3 847 $ au 31/03/2024
Profil
George Francis Tidmarsh is the founder of Threshold Pharmaceuticals, Inc. (founded in 2001), Nuveta, Inc. (founded in 2009), Horizon Therapeutics, Inc. (founded in 2005), Metronome Therapeutics, Inc. (founded in 2006), and Horizon Pharma, Inc. (founded in 2005).
He is currently the Chairman of Revelation Biosciences Sub, Inc., Revelation Biosciences, Inc., and Citizens Oncology Foundation.
He is also a Director at Lucile Packard Foundation for Children’s Health and an Associate Professor-Neonatology at Stanford University School of Medicine.
He has also served as a Director at Odonate, Inc. (2016-2019) and Principal at Gilead Sciences, Inc., SEQUUS Pharmaceuticals, Inc., and Systemix, Inc. Dr. Tidmarsh has a doctorate from Stanford University (1982) and a doctorate from Stanford University School of Medicine (1988).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/04/2024 | 1 404 ( 0,09% ) | 3 847 $ | 31/03/2024 |
Postes actifs de George Tidmarsh
| Sociétés | Poste | Début |
|---|---|---|
| REVELATION BIOSCIENCES, INC. | Chairman | 01/05/2020 |
Revelation Biosciences Sub, Inc.
 Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Chairman | - |
| Stanford University School of Medicine | Corporate Officer/Principal | 01/10/2010 |
| Citizens Oncology Foundation | Director/Board Member | - |
| Lucile Packard Foundation for Children’s Health | Director/Board Member | 01/01/2018 |
Anciens postes connus de George Tidmarsh
| Sociétés | Poste | Fin |
|---|---|---|
| ODONATE, INC. | Director/Board Member | 23/11/2019 |
| LA JOLLA PHARMACEUTICAL COMPANY | Chief Executive Officer | 23/11/2019 |
| ANAVEX LIFE SCIENCES CORP. | Director/Board Member | 27/03/2012 |
| Solana Therapeutics, Inc. | Chief Executive Officer | 01/01/2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de George Tidmarsh
| Stanford University | Doctorate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| ANAVEX LIFE SCIENCES CORP. | Health Technology |
| ODONATE, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Systemix, Inc.
 Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
InfaCare Pharmaceutical Corp.
 InfaCare Pharmaceutical Corp. BiotechnologyHealth Technology InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA. | Health Technology |
Nuveta, Inc.
 Nuveta, Inc. Medical SpecialtiesHealth Technology Nuveta, Inc. focused on the development and commercialization of new applications that significantly improve IVF therapy. It explored key scientific questions of in vitro embryo growth and uses these findings to create new methods. The company was founded by George Tidmarsh in 2009 and was headquartered in Portola Valley, CA. | Health Technology |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
Prospect Therapeutics, Inc.
 Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
Metronome Therapeutics, Inc.
 Metronome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metronome Therapeutics, Inc. manufactures and markets oncology drugs. It specializes in developing turnkey finished dosage forms of generic and drugs and has an affiliate assist producers of drugs in the diversification of their product portfolios. The company was founded by George Tidmarsh on January 13, 2006 and is headquartered in Delaware. | Health Technology |
| Lucile Packard Foundation for Children’s Health | Miscellaneous |
Horizon Pharma, Inc.
 Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
| Citizens Oncology Foundation | |
| Solana Therapeutics, Inc. | |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
| Revelation Biosciences, Inc. |
